Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$89.45

-0.6 (-0.67%)

, INCY

Incyte

$70.10

-0.3 (-0.43%)

18:33
07/19/18
07/19
18:33
07/19/18
18:33

Lancet study shows benefit of Baricitinib 4 mg for treatment of SLE

Eli Lilly (LLY) and Incyte (INCY) announced that results of a global systemic lupus erythematosus, or SLE, Phase 2 study for baricitinib were published by The Lancet. The study, the first completed Phase 2 study of a JAK inhibitor in SLE, showed that a statistically significant proportion of patients treated with 4 mg of baricitinib achieved resolution of their SLE-related arthritis or rash compared to placebo at week 24, the primary endpoint for the trial. Lilly plans to initiate Phase 3 trials to evaluate the safety and efficacy of baricitinib for the treatment of SLE in the second half of 2018. In the study, 314 patients were randomized 1:1:1 to receive placebo, baricitinib 2 mg or baricitinib 4 mg. Patients treated with 4 mg of baricitinib experienced improvements compared to placebo on several pre-specified secondary endpoints. Compared to placebo, a statistically significant greater proportion of patients treated with 4 mg of baricitinib experienced lower overall disease activity at week 24 as measured by the SLE Responder Index 4. A statistically significant greater proportion of patients treated with 4 mg of baricitinib achieved a state of low disease activity, as measured by the Lupus Low Disease Activity State, and experienced improvements in pain from baseline, two exploratory endpoints of the study. The percentage of patients stopping therapy through the 24-week treatment period was 21% in the placebo group, 18% in the 2-mg dosing group and 17% in the 4-mg dosing group. The most common treatment emergent adverse events in the baricitinib groups were upper respiratory tract infections, including viral upper respiratory infections, and urinary tract infections. The frequency of serious adverse events was 5% for placebo, 10.5% in the 2-mg dosing group and 9.6% in the 4-mg dosing group; the most common SAEs were serious infections. One case of deep vein thrombosis was reported in the 4-mg dosing group. There were no deaths, malignancies, major adverse cardiovascular events, tuberculosis, or serious herpes zoster infections.

LLY

Eli Lilly

$89.45

-0.6 (-0.67%)

INCY

Incyte

$70.10

-0.3 (-0.43%)

  • 24

    Jul

  • 31

    Jul

  • 10

    Sep

LLY Eli Lilly
$89.45

-0.6 (-0.67%)

07/17/18
CANT
07/17/18
NO CHANGE
CANT
Overweight
Aclaris offers best risk/reward of hair loss players, says Cantor Fitzgerald
The potential for JAK inhibitors to treat alopecia areata may be underappreciated by investors because the Street does not appear to be ascribing enough value to the opportunity, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Of the three companies she covers developing JAKs for hair loss, Aclaris Therapeutics (ACRS), Eli Lilly (LLY) and Pfizer (PFE), the analyst believes Aclaris offers the best risk/reward and greatest upside potential. The company has a market cap below $700M and two potential "shots on goal" for alopecia areata, Chen writes. She estimates combined peak sales of $1B-plus for both opportunities and keeps an Overweight rating on Aclaris. The physicians the analyst spoke to believe the company's JAKs for hair loss will work.
07/18/18
PIPR
07/18/18
NO CHANGE
Target $450
PIPR
Overweight
Piper maintains Overweight on Regeneron on tanezumab news
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) on news that tanezumab, Pfizer (PFE) and Eli Lilly's (LLY) anti-NGF antibody that is a competitor to Regeneron's fasinumab, successfully completed the first of several Phase 3 trials. Fasinumab remains an unmodeled opportunity, but the read-through from tanezumab is positive and the market for an effective, non-opioid chronic pain treatment is "massive," Raymond tells investors in a research note. The analyst points out that Regeneron and Teva (TEVA) still expect to report Phase 3 data starting later this year. Raymond keeps an Overweight rating on Regeneron with a $450 price target.
07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.
07/19/18
BMOC
07/19/18
NO CHANGE
Target $80
BMOC
Market Perform
Eli Lilly to have a 'good Q2' on beats from launch franchises, says BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Eli Lilly to $80 from $78 ahead of its Q2 earnings, saying the company will have a "good" quarter on "beats from its launch franchises Trulicity, Jardiance, and Basaglar". The analyst also keeps his Market Perform rating, adding that while the the pipeline potential of its Galcanezumab and Tanezumab drugs is promising, he believes investors are underappreciating the headwinds around its diabetes program. He see higher risks of an increased biosimilar erosion for Humalog from Sanofi's (SNY) Admelog, and Trulicity competitive pressure from Novo's (NVO) Ozempic in 2019.
INCY Incyte
$70.10

-0.3 (-0.43%)

07/13/18
MSCO
07/13/18
DOWNGRADE
Target $76
MSCO
Equal Weight
Incyte downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison downgraded Incyte to Equal Weight from Overweight as he believes key catalysts are unlikely until 2019 and he expects the stock to trade with the market in the meantime. However, Harrison said he is positive on the depth and diversity of the company's pipeline following the analyst day deep-dive and he thinks 2019 could be a pivotal year. He maintains a $76 price target on Incyte shares.
07/13/18
MSCO
07/13/18
DOWNGRADE
MSCO
Equal Weight
Incyte downgraded to Equal Weight from Overweight at Morgan Stanley
07/13/18
07/13/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AT&T (T) downgraded to Market Perform from Outperform at Raymond James with analyst Frank Louthan saying he views the Department of Justice appeal of the Time Warner case as a negative and said it is a "frustrating delay." Louthan expects the suit to be a "significant overhang" for an extended period of time, which will limit share appreciation, but remains confident AT&T will prevail. 2. Incyte (INCY) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Matthew Harrison saying he believes key catalysts are unlikely until 2019 and he expects the stock to trade with the market in the meantime. 3. WisdomTree (WETF) was downgraded to Market Perform from Outperform at Keefe Bruyette and to Neutral from Buy at Citi. 4. Cedar Fair (FUN) downgraded to Neutral from Outperform at Macquarie. 5. Ingredion (INGR) downgraded to Sell from Neutral at Citi with analyst David Driscoll saying he expects the stock's valuation multiples to compress as investors sort through the number of issues that have come to light. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/18/18
OPCO
07/18/18
NO CHANGE
Target $70
OPCO
Perform
Incyte price target raised to $70 from $65 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Incyte to $70 from $65 as several options in MPNs with combinations on top of Jakafi could solidify the franchise against potential competition, and early data will be available for several combinations in 2H18 and 2019. The analyst reiterates a Neutral rating on the shares.

TODAY'S FREE FLY STORIES

PINS

Pinterest

$26.69

0.68 (2.61%)

08:37
05/18/19
05/18
08:37
05/18/19
08:37
Periodicals
Pinterest committed 'cardinal sin' for newly public company, Barron's says »

Pinterest released its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSHB

KushCo Holdings

$0.00

(0.00%)

08:32
05/18/19
05/18
08:32
05/18/19
08:32
Periodicals
Pot paraphernalia companies taking hit from tariffs, Barron's says »

The U.S.-China trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

JWN

Nordstrom

$37.09

0.16 (0.43%)

08:24
05/18/19
05/18
08:24
05/18/19
08:24
Periodicals
Nordstrom stock a 'can't miss bargain.' Barron's says »

Nordstrom remains the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

NTDOY

Nintendo

$0.00

(0.00%)

, TTWO

Take-Two

$106.76

-0.81 (-0.75%)

08:10
05/18/19
05/18
08:10
05/18/19
08:10
Periodicals
Take-Two 'winning the game,' Barron's says »

Videogame stocks are down…

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$106.76

-0.81 (-0.75%)

DIS

Disney

$135.04

-0.46 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 24

    Jun

  • 13

    Nov

TPR

Tapestry

$30.78

-0.56 (-1.79%)

, REGN

Regeneron

$304.81

-4.69 (-1.52%)

08:01
05/18/19
05/18
08:01
05/18/19
08:01
Periodicals
Regeneron, Tapestry among cheap stocks to ride out trade war, Barron's says »

Applied Materials (AMAT),…

TPR

Tapestry

$30.78

-0.56 (-1.79%)

REGN

Regeneron

$304.81

-4.69 (-1.52%)

SCHW

Charles Schwab

$43.21

-0.94 (-2.13%)

BWA

BorgWarner

$36.27

-0.375 (-1.02%)

AMAT

Applied Materials

$42.72

-1.56 (-3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

  • 31

    May

  • 06

    Jun

  • 14

    Jun

  • 26

    Jun

  • 25

    Jul

MT

ArcelorMittal

$16.37

-0.485 (-2.88%)

, CLF

Cleveland-Cliffs

$10.02

-0.08 (-0.79%)

07:25
05/18/19
05/18
07:25
05/18/19
07:25
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

MT

ArcelorMittal

$16.37

-0.485 (-2.88%)

CLF

Cleveland-Cliffs

$10.02

-0.08 (-0.79%)

SCHN

Schnitzer Steel

$23.16

0.42 (1.85%)

BRSS

Global Brass and Copper

$43.09

-0.01 (-0.02%)

LXFR

Luxfer

$25.41

-0.44 (-1.70%)

MTRN

Materion

$66.36

0.155 (0.23%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$14.84

-0.01 (-0.07%)

F

Ford

$10.29

-0.1 (-0.96%)

GM

General Motors

$37.00

-0.36 (-0.96%)

HMC

Honda

$25.64

-0.135 (-0.52%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.40

-1.44 (-1.20%)

VWAGY

Volkswagen

$0.00

(0.00%)

SHOO

Steven Madden

$31.49

-0.37 (-1.16%)

GIII

G-III Apparel

$31.82

-0.35 (-1.09%)

IIVI

II-VI

$32.66

-1.64 (-4.78%)

LITE

Lumentum

$46.30

-4.15 (-8.23%)

MU

Micron

$36.06

-1.37 (-3.66%)

WDC

Western Digital

$44.62

-0.82 (-1.80%)

COHR

Coherent

$121.28

-5.22 (-4.13%)

LASR

nLight

$21.21

-1.27 (-5.65%)

VECO

Veeco

$12.50

-0.25 (-1.96%)

NPTN

NeoPhotonics

$3.83

-0.7 (-15.45%)

AAPL

Apple

$188.97

-0.93 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 28

    May

  • 29

    May

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 23

    Oct

WMT

Walmart

$100.88

-0.56 (-0.55%)

17:59
05/17/19
05/17
17:59
05/17/19
17:59
Hot Stocks
Walmart EVP Furner sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 15

    Aug

  • 13

    Nov

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

, REPYY

Repsol

$0.00

(0.00%)

17:56
05/17/19
05/17
17:56
05/17/19
17:56
Periodicals
Exxon Gulf of Mexico sale gets interest from Repsol, Ineos, Bloomberg says »

Exxon Mobil (XOM) has…

XOM

Exxon Mobil

$75.91

-0.44 (-0.58%)

REPYY

Repsol

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

IEF

iShares 7-10 Year Treasury Bond ETF

$106.74

0.04 (0.04%)

, SHY

iShares 1-3 Year Treasury Bond

$84.15

0.02 (0.02%)

17:43
05/17/19
05/17
17:43
05/17/19
17:43
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$106.74

0.04 (0.04%)

SHY

iShares 1-3 Year Treasury Bond

$84.15

0.02 (0.02%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

SLV

iShares Silver Trust

$13.52

-0.14 (-1.02%)

GLD

SPDR Gold Shares

$120.64

-0.86 (-0.71%)

FXE

Euro Currency Trust

$106.35

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

17:39
05/17/19
05/17
17:39
05/17/19
17:39
Periodicals
IMF's Lagarde: U.S.-China trade spat may be risk to global economy, Reuters says »

IMF managing director…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.98

-1.87 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIG

Hartford Financial

$53.58

-0.02 (-0.04%)

17:34
05/17/19
05/17
17:34
05/17/19
17:34
Syndicate
Breaking Syndicate news story on Hartford Financial »

Hartford Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

AFH

Atlas Financial

$0.91

0.0225 (2.53%)

17:33
05/17/19
05/17
17:33
05/17/19
17:33
Hot Stocks
Atlas Financial receives filing delinquency notice from Nasdaq »

Atlas Financial received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WES

Western Gas Partners

$30.60

-0.155 (-0.50%)

17:29
05/17/19
05/17
17:29
05/17/19
17:29
Syndicate
Breaking Syndicate news story on Western Gas Partners »

Western Gas Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$354.99

0.5 (0.14%)

17:24
05/17/19
05/17
17:24
05/17/19
17:24
Hot Stocks
Boeing awarded $163.91M Navy contract modification »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

LMT

Lockheed Martin

$338.10

-2.39 (-0.70%)

17:18
05/17/19
05/17
17:18
05/17/19
17:18
Hot Stocks
Lockheed Martin subsidiary awarded $1.13B Navy contract modification »

Sikorsky, a Lockheed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

COTY

Coty

$13.50

0.25 (1.89%)

17:14
05/17/19
05/17
17:14
05/17/19
17:14
Hot Stocks
Coty exec Pieraccioni acquires 93,100 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMR

Alta Mesa Resources

$0.18

-0.0027 (-1.50%)

17:14
05/17/19
05/17
17:14
05/17/19
17:14
Hot Stocks
Alta Mesa Resources receives noncompliance notification from Nasdaq »

Nasdaq notified Alta Mesa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NJR

New Jersey Resources

$49.82

-0.03 (-0.06%)

17:06
05/17/19
05/17
17:06
05/17/19
17:06
Hot Stocks
New Jersey Resources' Trice sells 12,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

AHC

A.H. Belo

$3.82

-0.075 (-1.93%)

17:03
05/17/19
05/17
17:03
05/17/19
17:03
Hot Stocks
A.H. Belo sells former Dallas Morning News campus for $31.6M »

A. H. Belo announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRA

Telaria

$8.56

0.2 (2.39%)

17:01
05/17/19
05/17
17:01
05/17/19
17:01
Hot Stocks
Telaria director Rossman sells 173K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 10

    Jun

HL

Hecla Mining

$1.53

0.015 (0.99%)

16:58
05/17/19
05/17
16:58
05/17/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INNT

Innovate Biopharmaceuticals

$1.59

-0.095 (-5.65%)

16:57
05/17/19
05/17
16:57
05/17/19
16:57
Syndicate
Breaking Syndicate news story on Innovate Biopharmaceuticals »

Innovate files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 31

    May

JONE

Jones Energy

$0.00

(0.00%)

16:56
05/17/19
05/17
16:56
05/17/19
16:56
Hot Stocks
Jones Energy emerges from bankruptcy »

Jones Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPP

Hudson Pacific

$34.33

-0.15 (-0.44%)

16:44
05/17/19
05/17
16:44
05/17/19
16:44
Hot Stocks
Hudson Pacific CFO sells ~57K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

GLYC

GlycoMimetics

$12.42

-0.43 (-3.35%)

16:36
05/17/19
05/17
16:36
05/17/19
16:36
Syndicate
Breaking Syndicate news story on GlycoMimetics »

GlycoMimetics files $250M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.